← Back to Clinical Trials
Recruiting Phase 4 NCT04166877

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

Trial Parameters

Condition Trauma
Sponsor University of California, Davis
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 156
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-12-07
Completion 2026-12-31
All Conditions
Interventions
Magnesium Sulfate in Parenteral Dosage FormNormal saline placebo

Brief Summary

Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in decreasing narcotic (pain reliever) requirements and provide another non-narcotic drug for pain control. The purpose of this study is to test the effectiveness of continuous, intravenous (into or within a vein using a needle) administration of magnesium sulfate for pain control in trauma patients admitted to the adult Intensive Care Unit. This will be compared to intravenous normal saline (salt solution).

Eligibility Criteria

Inclusion Criteria: * All trauma patients admitted to an adult intensive care unit * Signed informed consent * Hospital or trauma multimodal pain management order set used for pain management * Ages 18-99 Exclusion Criteria: * Admission to the Pediatric Intensive Care Unit. * Head Abbreviated Injury Score (AIS) of greater than 1 * Known heart failure with reduced ejection fraction (EF \< 40%) * Renal failure (GFR \< 60) * Cardiac arrhythmia (except for sinus tachycardia) * Greater than 5% TBSA burn injuries * Moderate to severe alcohol withdrawal protocol ordered for patient * Regular use of opioids in the week prior to injury * Receiving continuous infusion of opioids * Patients expected to require general anesthesia between 24 and 48 hours after admission (during study drug administration) * Patients unable to provide consent is unavailable * Patients unable to provide a pain score * Pregnancy * Prisoners

Related Trials